BR112016021000A2 - Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf) - Google Patents
Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf)Info
- Publication number
- BR112016021000A2 BR112016021000A2 BR112016021000A BR112016021000A BR112016021000A2 BR 112016021000 A2 BR112016021000 A2 BR 112016021000A2 BR 112016021000 A BR112016021000 A BR 112016021000A BR 112016021000 A BR112016021000 A BR 112016021000A BR 112016021000 A2 BR112016021000 A2 BR 112016021000A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- seq
- amino acid
- acid sequence
- pulmonary fibrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
Abstract
COMPOSIÇÕES E MÉTODOS PARA PREVENIR OU TRATAR DISFUNÇÃO CRÔNICA DO ALOENXERTO DE PULMÃO (CLAD) E FIBROSE PULMONAR IDIOPÁTICA (IPF). A invenção descrita fornece composições e métodos para reduzir a disfunção de aloenxerto pulmonar após transplante de pulmão e para o tratamento de uma fibrose pulmonar grave distinguida pela proliferação anormal de fibroblastos e deposição de matriz extracelular em um tecido de um sujeito. Os métodos compreendem a administração a um sujeito em necessidade do mesmo de uma composição que compreende um componente de anticorpo que compreende uma quantidade terapêutica de um anticorpo anti-CD44; e um componente de inibidor de MK2 que compreende uma quantidade terapêutica de um polipeptídeo inibidor de MK2 (MK2i) da sequência de aminoácidos YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) ou pelo menos um peptídeo funcionalmente equivalente ao domínio terapêutico do mesmo selecionado a partir de um polipeptídeo da sequência de aminoácidos KALARQLAVA (SEQ ID NO: 8), um polipeptídeo da sequência de aminoácidos KALARQLGVA (SEQ ID NO: 9) e um polipeptídeo da sequência de aminoácidos KALARQLGVAA (SEQ ID NO: 1) ou um equivalente funcional do mesmo e um veículo farmaceuticamente aceitável.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953438P | 2014-03-14 | 2014-03-14 | |
| PCT/US2015/020263 WO2015138784A2 (en) | 2014-03-14 | 2015-03-12 | Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016021000A2 true BR112016021000A2 (pt) | 2017-10-03 |
Family
ID=54067793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016021000A BR112016021000A2 (pt) | 2014-03-14 | 2015-03-12 | Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150258192A1 (pt) |
| EP (1) | EP3116543A4 (pt) |
| JP (1) | JP6655547B2 (pt) |
| KR (1) | KR20160124236A (pt) |
| CN (1) | CN106456758A (pt) |
| AU (1) | AU2015229251A1 (pt) |
| BR (1) | BR112016021000A2 (pt) |
| CA (1) | CA2942517A1 (pt) |
| MX (1) | MX2016011852A (pt) |
| RU (1) | RU2016140332A (pt) |
| SG (1) | SG11201607627RA (pt) |
| WO (1) | WO2015138784A2 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017053952A1 (en) | 2015-09-25 | 2017-03-30 | Cedars-Sinai Medical Center | Targeting fibroblast invasion for pulmonary fibrosis |
| US11725056B2 (en) | 2017-10-03 | 2023-08-15 | Cedars-Sinai Medical Center | Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis |
| WO2020237587A1 (en) * | 2019-05-30 | 2020-12-03 | National Institute Of Biological Sciences, Beijing | Animal model of idiopathic pulmonary fibrosis, its construction method and use |
| WO2022020562A1 (en) * | 2020-07-24 | 2022-01-27 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
| CN112575074B (zh) * | 2020-10-09 | 2022-12-27 | 中山大学 | Nestin基因及蛋白在治疗器官纤维化中的应用 |
| US20220202852A1 (en) * | 2020-12-30 | 2022-06-30 | Briotech, Inc. | Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2560200A1 (en) * | 2004-03-17 | 2005-09-22 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Cd44-targeting for reducing/preventing ischemia-reperfusion-injury |
| US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20080199426A1 (en) * | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
| US10232039B2 (en) * | 2011-04-12 | 2019-03-19 | Duke University | Compositions and methods for the treatment of tissue fibrosis |
| SG194135A1 (en) * | 2011-04-12 | 2013-11-29 | Matrix Inc Moerae | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
-
2015
- 2015-03-12 SG SG11201607627RA patent/SG11201607627RA/en unknown
- 2015-03-12 MX MX2016011852A patent/MX2016011852A/es unknown
- 2015-03-12 EP EP15761995.8A patent/EP3116543A4/en not_active Withdrawn
- 2015-03-12 KR KR1020167028395A patent/KR20160124236A/ko not_active Application Discontinuation
- 2015-03-12 RU RU2016140332A patent/RU2016140332A/ru not_active Application Discontinuation
- 2015-03-12 AU AU2015229251A patent/AU2015229251A1/en not_active Abandoned
- 2015-03-12 CA CA2942517A patent/CA2942517A1/en not_active Abandoned
- 2015-03-12 JP JP2016557276A patent/JP6655547B2/ja not_active Expired - Fee Related
- 2015-03-12 BR BR112016021000A patent/BR112016021000A2/pt not_active Application Discontinuation
- 2015-03-12 US US14/656,492 patent/US20150258192A1/en not_active Abandoned
- 2015-03-12 CN CN201580025482.9A patent/CN106456758A/zh active Pending
- 2015-03-12 WO PCT/US2015/020263 patent/WO2015138784A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN106456758A (zh) | 2017-02-22 |
| CA2942517A1 (en) | 2015-09-17 |
| KR20160124236A (ko) | 2016-10-26 |
| WO2015138784A3 (en) | 2015-10-29 |
| US20150258192A1 (en) | 2015-09-17 |
| JP2017509633A (ja) | 2017-04-06 |
| SG11201607627RA (en) | 2016-10-28 |
| EP3116543A4 (en) | 2017-09-06 |
| EP3116543A2 (en) | 2017-01-18 |
| JP6655547B2 (ja) | 2020-02-26 |
| AU2015229251A1 (en) | 2016-09-22 |
| RU2016140332A3 (pt) | 2018-10-11 |
| MX2016011852A (es) | 2017-05-09 |
| WO2015138784A2 (en) | 2015-09-17 |
| RU2016140332A (ru) | 2018-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016021000A2 (pt) | Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf) | |
| UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| BR112018000903A2 (pt) | composições e métodos para o tratamento de câncer | |
| BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| IN2014KN01713A (pt) | ||
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| GT201700224A (es) | Proteína de unión a rgma y su uso | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| MX2019008949A (es) | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. | |
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| BR112018070819A2 (pt) | peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| CO2020004244A2 (es) | Métodos y composiciones para tratar enfermedades pulmonares crónicas | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| MX2017008505A (es) | Composicion. | |
| PH12015502037A1 (en) | Activating adiponectin by casein hydrolysate | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| MX2017013480A (es) | Composicion farmaceutica para tratar y/o prevenir el cancer. | |
| BR112018001207A2 (pt) | novo peptídeo e uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |